Adjuvant Pembrolizumab Improves Distant Metastasis–Free Survival in Resected Stage IIB and IIC Melanoma
Source: OncLive, March 2022
Pembrolizumab (Keytruda) significantly improved distant metastasis–free survival (DMFS) vs placebo when used as an adjuvant treatment in patients with resected stage IIB and IIC melanoma, according to additional data from the phase 3 KEYNOTE-716 trial (NCT03553836).1
Previously, in December 2021, the FDA approved pembrolizumab for the adjuvant treatment of adult and pediatric patients with stage IIB or IIC melanoma following complete resection based on data from the first interim analysis of KEYNOTE-716, which showed that the immunotherapy significantly improved recurrence-free survival (RFS) vs placebo, reducing the risk of disease recurrence or death by 35% (HR, 0.65; 95% CI, 0.46-0.92; P = .0132).2
READ THE ORIGINAL FULL ARTICLE